Related Experiment Video

Updated: Aug 18, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Diazoxide-mediated insulin suppression in obese men: a dose-response study

T Schreuder1, M Karreman, A Rennings

  • 1Department of Internal Medicine, Ziekenhuis Rijnstate, Wagnerlaan 55, 6800 TA Arnhem, The Netherlands.

Diabetes, Obesity & Metabolism
|April 7, 2005
PubMed
Abstract

Insights

Diazoxide (DZX) shows dose-dependent insulin suppression, but its efficacy is reduced in obese individuals due to lower plasma DZX levels. Weight-adjusted dosing is crucial for effective insulin suppression in obese men.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Diazoxide (DZX) is investigated for its potential to suppress insulin and promote weight loss in obese individuals.
  • Hyperinsulinemia in obese subjects necessitates exploring effective insulin-suppressing agents.

Purpose of the Study:

  • To determine a safe and effective dose range of diazoxide (DZX) for obese, hyperinsulinemic men.
  • To compare the efficacy and safety of DZX in obese versus non-obese individuals.

Main Methods:

  • Open-label study in non-obese men to assess DZX efficacy.
  • Double-blind, placebo-controlled trial in obese men using DZX doses of 50, 75, and 100 mg thrice daily for 6 days.
  • Evaluation of plasma glucose and insulin responses to a standardized breakfast on day 6 of treatment.

Main Results:

  • In non-obese men, DZX (50-100 mg) dose-dependently reduced peak insulin levels and increased peak glucose levels.
  • In obese men, DZX doses of 50 and 75 mg showed no significant effects on glucose or insulin.
  • DZX 100 mg reduced peak insulin by ~20% in obese men, but fasting/postprandial glucose remained unaffected. Obese subjects exhibited ~30% lower plasma DZX levels than non-obese subjects at comparable doses, attributed to weight-dependent distribution.
  • Plasma DZX levels were significantly correlated with dose (p < 0.001) and body weight (p < 0.001).

Conclusions:

  • Diazoxide-mediated insulin suppression is dose-dependent but significantly less effective in obese individuals compared to non-obese individuals.
  • Lower plasma DZX levels in obese subjects, due to increased distribution volume, limit its efficacy.
  • Weight-adjusted DZX doses, estimated at 3.2-4.2 mg/kg daily, are required to achieve effective insulin suppression in obese men.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...